Dr. Chris Gemmiti, VP Operations at Sentien, will be speaking on an Outsourcing vs. Insourcing panel on September 10, 2019.

Dr. Rita Barcia, Executive Director of R&D at Sentien, will be speaking on a Next Generation Therapies panel on September 12, 2019.

Sentien Biotechnologies Scientific Co-Founder, Dr. Biju Parekkadan, will be speaking at the American Society of Gene & Cell Therapy Annual Meeting on April 29, 2019 in Washington, DC.  He will be discussing Reprogramming Human Immune Responses Using Ex Vivo MSC Bioreactor Therapy.

Sentien Biotechnologies CEO Brian Miller will be presenting at the Alliance of Regenerative Medicine (ARM) Cell & Gene Therapy Investor Day on March 21, 2019 in New York, NY.

Dr. Chris Gemmiti will be attending Phacilitate at the Hyatt Regency in Miami this January. Please reach out to schedule a time to meet with him and learn more about the Sentien approach.
SCHEDULE A MEETING >

The Sentien team will be attending the 2019 J.P. Morgan Healthcare Conference. This event continues to be one of the life science industry’s largest conferences of the year. Contact us today to schedule a time to meet with our team and learn more about our business.
SCHEDULE A MEETING >

Watch Dr. Parekkadan’s interview at the World Advanced Therapies & Regenerative Medicine Congress in London here!
SEE VIDEO >

Watch Dr. Parekkadan’s TEDx Talk here!
SEE VIDEO >

Watch Sentien CEO Brian Miller’s presentation from the 2017 Cell & Gene Meeting on the Mesa here!
SEE VIDEO >

In September, our clinical trial was selected by Cell Trials Data as its Featured Advanced Cell Therapy Trial.
READ MORE >

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, announced that it has opened enrollment in its Phase 1/2 trial of SBI-101 for adult patients with acute kidney injury (AKI). This trial is Sentien’s first clinical program.
READ MORE >